LOS ANGELES (Reuters) - A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday. "For some people a higher dose may work better," said Dr. Jeffrey Cohen of the Cleveland Clinic's MS research center and lead investigator of a small nine-month trial comparing the two doses. The study, funded by Israel-based Teva, found that a 40 milligram injection of Copaxone reduced inflammatory disease activity 38 percent more than a 20 mg dose. Rates of side effects, mainly...